Get started
Author

Mathilde Couëtoux du Tertre

Observed names: M. Couetoux Du Tertre, M. Couetoux du Tertre, Mathilde Couetoux, Mathilde Couetoux de Tertre, Mathilde Couetoux du Tertre, Mathilde Couetoux du Tertre1, Tertre, Mathilde Couëtoux Du
ORCID: 0000-0003-1982-1936
Observed ORCID: 0000-0003-1982-1936
OpenAlex ID: A5042901839
A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens
2018 · Miguel Alcaide, Matthew Cheung, et al. · Journal of Molecular Diagnostics · 41
PDF
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2019 · Mathilde Couëtoux du Tertre, Maud Marques, et al. · Molecular Cancer Therapeutics · 28
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data
2019 · Bernhard Blank-Landeshammer, Vincent R. Richard, et al. · Cancers · 26
PDF
Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits
2017 · Miguel Alcaide, Stephen Yu, et al. · Scientific Reports · 25
PDF
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer
2021 · Karen Gambaro, Maud Marques, et al. · Clinical and Translational Medicine · 12
PDF
Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer
2019 · Sudhir Sinha, Hiromi Brown, et al. · Surgery · 12
PDF
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
2023 · Karen Gambaro, Maud Marques, et al. · International Journal of Molecular Sciences · 2
PDF
Abstract 6494: Personalize My Treatment (PMT): A pan-Canadian initiative integrating precision oncology across Canada - PMT-001 pilot project
2020 · Maud Marques, Karen Gambaro, et al. · Cancer Research · 2
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition
2020 · Mathilde Couëtoux du Tertre, Maud Marques, et al. · Clinical Proteomics · 2
PDF
Abstract 5575: A multiplexed RE-qPCR cell-free DNA assay to assess response and resistance to cancer therapy
2018 · Sudhir K. Sinha, Hiromi Brown, et al. · Cancer Research · 1
Molecular predictors of long-term response to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients.
2018 · Mathilde Couetoux du Tertre, Maud Marques, et al. · Journal of Clinical Oncology · 1
Data from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Figure 1 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 2 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Figure 2 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 3 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 1 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 4 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 3 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Supplementary Table 4 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Data from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
2023 · Mathilde Couëtoux du Tertre, Maud Marques, et al.
Abstract 4325: A Phase II exploratory study to identify biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer who have failed first-line therapy
2020 · Karen Gambaro, Maud Marques, et al. · Cancer Research
Abstract A07: Sequential ctDNA analysis detected preclinical relapse in patients with metastatic colorectal cancer from the Exactis trial (NCT00984048)
2020 · Melissa K. McConechy, Suzan McNamara, et al. · Clinical Cancer Research
Additional file 7 of Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition
2020 · Tertre, Mathilde Couëtoux Du, Marques, Maud, et al. · Figshare
Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy
2019 · K. Gambaro, M. Marques, et al. · Annals of Oncology
PDF
Works count: 35
Citation count: 152
H-index: 6
I10-index: 6
Year
Topic
Type